Cargando…
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
PURPOSE: Anti-PD-1 antibody improves the survival of patients with advanced melanoma. However, the efficacy and safety of anti-programmed death protein 1 (PD-1) antibody have not been fully elucidated in Chinese melanoma patients, who show high frequency of mucosal and acral melanoma subtypes; besid...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791241/ https://www.ncbi.nlm.nih.gov/pubmed/31662753 http://dx.doi.org/10.1155/2019/6454989 |
_version_ | 1783458949295505408 |
---|---|
author | Zhao, Lingdi Yang, Yonghao Ma, Baozhen Li, Wei Li, Tiepeng Han, Lu Zhang, Yong Shang, Yi-Man Lin, Hongwei Gao, Quanli |
author_facet | Zhao, Lingdi Yang, Yonghao Ma, Baozhen Li, Wei Li, Tiepeng Han, Lu Zhang, Yong Shang, Yi-Man Lin, Hongwei Gao, Quanli |
author_sort | Zhao, Lingdi |
collection | PubMed |
description | PURPOSE: Anti-PD-1 antibody improves the survival of patients with advanced melanoma. However, the efficacy and safety of anti-programmed death protein 1 (PD-1) antibody have not been fully elucidated in Chinese melanoma patients, who show high frequency of mucosal and acral melanoma subtypes; besides, the factors influencing the efficacy of anti-PD-1 antibody have not been evaluated broadly. PATIENTS AND METHODS: Patients with advanced melanoma treated with regimens containing anti-PD-1 antibody from June 2016 to January 2019 were evaluated. Baseline characteristics and blood parameters were assessed, and outcome and adverse events were evaluated according to different regimens. The Cox proportional hazards regression model was used for univariate and multivariate analyses. RESULTS: A total of 51 patients with advanced melanoma were included in this study. The overall objective response rate (ORR) was 17.6%, the disease control rate was 58.5%, and the median time to progression was 5.2 months. The ORR of patients with PD-1 blockade-based combination therapy, without liver metastases and higher level of C-reactive protein (CRP) before PD-1 blockade, is higher than that of those not. Univariate analysis based on clinical features showed that ECOG scores, liver metastasis, elevated lactate dehydrogenase (LDH), and CRP levels were the factors affecting time to progression (TTP). Multivariate analysis showed that elevated CRP before PD-1 blockade was an independent predictive factor for ORR of PD-1 blockade therapy (P=0.009), while only Eastern Cooperative Oncology Group (ECOG) score was an independent predictor for TTP (P=0.032). The treatment was well tolerated in these cohort patients, and there was no treatment-related death. CONCLUSION: Anti-PD-1 antibody-containing regimen was safe and effective in Chinese patients with advanced melanoma, and elevated CRP and ECOG score were independent factors predicting the efficacy of anti-PD-1 therapy. |
format | Online Article Text |
id | pubmed-6791241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-67912412019-10-29 Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma Zhao, Lingdi Yang, Yonghao Ma, Baozhen Li, Wei Li, Tiepeng Han, Lu Zhang, Yong Shang, Yi-Man Lin, Hongwei Gao, Quanli J Oncol Research Article PURPOSE: Anti-PD-1 antibody improves the survival of patients with advanced melanoma. However, the efficacy and safety of anti-programmed death protein 1 (PD-1) antibody have not been fully elucidated in Chinese melanoma patients, who show high frequency of mucosal and acral melanoma subtypes; besides, the factors influencing the efficacy of anti-PD-1 antibody have not been evaluated broadly. PATIENTS AND METHODS: Patients with advanced melanoma treated with regimens containing anti-PD-1 antibody from June 2016 to January 2019 were evaluated. Baseline characteristics and blood parameters were assessed, and outcome and adverse events were evaluated according to different regimens. The Cox proportional hazards regression model was used for univariate and multivariate analyses. RESULTS: A total of 51 patients with advanced melanoma were included in this study. The overall objective response rate (ORR) was 17.6%, the disease control rate was 58.5%, and the median time to progression was 5.2 months. The ORR of patients with PD-1 blockade-based combination therapy, without liver metastases and higher level of C-reactive protein (CRP) before PD-1 blockade, is higher than that of those not. Univariate analysis based on clinical features showed that ECOG scores, liver metastasis, elevated lactate dehydrogenase (LDH), and CRP levels were the factors affecting time to progression (TTP). Multivariate analysis showed that elevated CRP before PD-1 blockade was an independent predictive factor for ORR of PD-1 blockade therapy (P=0.009), while only Eastern Cooperative Oncology Group (ECOG) score was an independent predictor for TTP (P=0.032). The treatment was well tolerated in these cohort patients, and there was no treatment-related death. CONCLUSION: Anti-PD-1 antibody-containing regimen was safe and effective in Chinese patients with advanced melanoma, and elevated CRP and ECOG score were independent factors predicting the efficacy of anti-PD-1 therapy. Hindawi 2019-09-26 /pmc/articles/PMC6791241/ /pubmed/31662753 http://dx.doi.org/10.1155/2019/6454989 Text en Copyright © 2019 Lingdi Zhao et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhao, Lingdi Yang, Yonghao Ma, Baozhen Li, Wei Li, Tiepeng Han, Lu Zhang, Yong Shang, Yi-Man Lin, Hongwei Gao, Quanli Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma |
title | Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma |
title_full | Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma |
title_fullStr | Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma |
title_full_unstemmed | Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma |
title_short | Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma |
title_sort | factors influencing the efficacy of anti-pd-1 therapy in chinese patients with advanced melanoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791241/ https://www.ncbi.nlm.nih.gov/pubmed/31662753 http://dx.doi.org/10.1155/2019/6454989 |
work_keys_str_mv | AT zhaolingdi factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT yangyonghao factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT mabaozhen factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT liwei factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT litiepeng factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT hanlu factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT zhangyong factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT shangyiman factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT linhongwei factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma AT gaoquanli factorsinfluencingtheefficacyofantipd1therapyinchinesepatientswithadvancedmelanoma |